KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.

David J Lewis, Mats Jerkeman, Lexy Sorrell, David Wright, Ingrid Glimelius, Christian B Poulsen, Annika Pasanen, Andrew Rawstron, Karin F Wader, Nick Morley, Catherine Burton, Andrew J Davies, Ingemar Lagerlöf, Surita Dalal, Ruth De Tute, Chris McNamara, Nicola Crosbie, Helle Erbs Toldbod, Jeanette Sanders, Victoria Allgar, Sree Aroori, Mark Warner, Claire Scully, Brian Wainman, Jacob Haaber Christensen, Jon Riise, Kristina Sonnevi, Mark J Bishton, Toby A Eyre, Simon Rule, ENRICH investigators

Lancet 406(10514) 1953-1968

PMID41052510
PMCIDPMC12549478
DOI10.1016/S0140-6736(25)01432-1
发表日期2025-10-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Ibrutinib, a Bruton tyrosine kinase inhibitor, prolongs progression-free survival when added to immunochemotherapy as first line treatment. The ENRICH trial compared the chemotherapy-free combination of ibrutinib and the anti-CD20 antibody rituximab (ibrutinib-rituximab) with standard immunochemotherapy (R-CHOP [rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone] or bendamustine-rituximab) in patients 60 years and older with untreated mantle-cell lymphoma. METHODS: This randomised, open-label, phase 2/3 superiority trial was performed at 66 sites in the UK, Sweden, Norway, Finland, and Denmark. Patients 60 years and older with untreated mantle-cell lymphoma (Ann-Arbor stage II-IV disease, an Eastern Cooperative Oncology Group performance-status score of 0-2) were randomly assigned to receive either rituximab plus immunochemotherapy or ibrutinib-rituximab in a 1:1 ratio, stratified by investigator choice of immunochemotherapy. Patients randomly allocated to the ibrutinib-rituximab (intervention) group received 560 mg oral ibrutinib daily in combination with six to eight cycles of 375 mg/m2 intravenous rituximab on day 1 of each cycle in the matched schedule of the pre-randomisation choice of immunochemotherapy (every 21 days for R-CHOP or every 28 days for rituximab-bendamustine). R-CHOP comprised 750 mg/m2 of cyclophosphamide, 50 mg/m2 of doxorubicin, and 1·4 mg/m2 vincristine on day 1 of each 21-day cycle, with 100 mg prednisolone on days 1-5 of each cycle. Rituximab-bendamustine comprised 90 mg/m2 of bendamustine on days 1 and 2 of each cycle, in combination with 375 mg/m2 rituximab on day 1 of each cycle. All responding patients in both groups at the end of induction received maintenance rituximab administered every 8 weeks for 2 years, and patients allocated to the intervention group continued ibrutinib until disease progression or unacceptable toxicity. The primary outcome was investigator-assessed progression-free survival, stratified by immunochemotherapy choice and analysed in the intention-to-treat population. The trial was registered with EudraCT (2015-000832-13) and is closed for recruitment. FINDINGS: Between Feb 15, 2016, and June 30, 2021, 397 patients were randomly allocated to immunochemotherapy (control) or ibrutinib-rituximab (intervention). Of the 397, 107 (27%) were pre-allocated to the immunochemotherapy choice of R-CHOP and 290 (73%) were pre-allocated to rituximab-bendamustine. In total, 198 were allocated to the control group (53 to R-CHOP and 145 to bendamustine-rituximab) and 199 were allocated to intervention. The median age was 74 years (IQR 70-77) for the intervention group and 74 years (70-78) in the control group. 296 patients (75%) were male and 101 patients (25%) were female; ethnicity data were not collected. At a median follow-up of 47·9 months, the median progression-free survival of ibrutinib-rituximab was superior to immunochemotherapy, with an adjusted hazard ratio (HR) of 0·69 (95% CI 0·52-0·90); p=0·0034. For those with pre-randomisation choice R-CHOP, the HR was 0·37 (0·22-0·62), and with bendamustine-rituximab, the HR was 0·91 (0·66-1·25). Across induction and maintenance, 67% of patients assigned to ibrutinib-rituximab and 70% of patients receiving immunotherapy reported grade 3 or above adverse events. INTERPRETATION: To our knowledge, this is the first randomised trial in untreated mantle-cell lymphoma to demonstrate significant improvement in progression-free survival for ibrutinib-rituximab compared to immunochemotherapy. This study suggests that ibrutinib-rituximab should be considered a new standard of care option for first-line treatment of older patients with mantle-cell lymphoma. FUNDING: Cancer Research UK (C7627/A17938) and Johnson and Johnson Pharmaceuticals.

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2 Progression-free survival Kaplan–Meier curves for all patients (A), the R-CHOP choice group (B), and the bendamustine–rituximab choice group (C) Progression-free survival Kaplan–Meier curves for the intention-to-treat population. (A) Overall Kaplan–Meier curve for ibrutinib–rituximab versus immunochemotherapy. (B) Pre-randomisation investigator choice of R-CHOP (ibrutinib–rituximab vs R-CHOP). (C) Pre-randomisation investigator choice of bendamustine–rituximab (ibrutinib–rituximab vs bendamustine–rituximab). HR=hazard ratio. R-CHOP=rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone.

A

progression-free survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

progression-free survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

progression-free survival

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure3 个面板

Figure 4

Figure 4 Overall survival Kaplan–Meier curves for all patients (A), the R-CHOP choice group (B) and the bendamustine–rituximab choice group (C) Overall survival Kaplan–Meier curves of the intention-to-treat population. (A) Overall Kaplan–Meier curve for ibrutinib–rituximab versus immunochemotherapy. (B) Pre-randomisation investigator choice of R-CHOP (ibrutinib–rituximab vs R-CHOP). (C) Pre-randomisation investigator choice of rituximab plus bendamustine (ibrutinib–rituximab vs bendamustine–rituximab). R-CHOP=rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone.

A

Overall survival

Figure 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
B

Overall survival

Figure 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Overall survival

Figure 4 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 ENRICH trial profile The trial profile details the ENRICH treatment pathway for participants. Not all progressions of disease or deaths are listed, as events might occur once a participant has discontinued ENRICH treatment (appendix pp 32, 36). GI=gastrointestinal. MCL=mantle-cell lymphoma. R-CHOP=rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone. *One death for each named cause.
非 KM Figure
Figure 3Figure 3 Subgroup analysis of progression-free survival Subgroup analysis of progression-free survival by treatment allocation, adjusted hazard ratios for ibrutinib–rituximab or immunochemotherapy. (A) Ibrutinib–rituximab versus immunochemotherapy where all comparisons are adjusted for the pre-randomisation investigator choice of immunochemotherapy. (B) Pre-randomisation investigator choice of R-CHOP (ibrutinib–rituximab vs R-CHOP). (C) Pre-randomisation investigator choice of bendamustine–rituximab (ibrutinib–rituximab vs bendamustine-rituximab). Analysis of subgroups MIPI and Ki67 with multiple imputation for missing grouping values are provided in the appendix (p 42). ECOG=Eastern Cooperative Oncology Group. MIPI=Mantle Cell Lymphoma International Prognostic Index. R-CHOP=rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone.
非 KM Figure